Medical and Ethical Issues Cloud Plans to Clone for Therapy
By Andrew Pollack,
The New York Times
| 02. 13. 2004
In cloning human embryos and extracting universal stem cells,
scientists in South Korea have taken a big step toward a tantalizing
goal: growing tailor-made replacement tissues for people who are sick
or injured. Imagine new cardiac muscles to restore a heart after a
heart attack, insulin-producing cells for diabetics or neurons to stave
off Parkinson's disease.
But significant scientific
barriers lie between this accomplishment and any actual therapy,
experts said. Moreover, ethical objections have put such research
off-limits to some scientists - including the many in the United States
who rely on federal money - and lack of investment has felled many
companies trying to develop cell-replacement therapies.
The
South Korean work is a step toward what is called "therapeutic
cloning." The work so far is "proof of concept of cloning but it's not
therapeutic yet," said Dr. Steven A. Goldman, chief of the division of
cell and gene therapy at the University of Rochester Medical Center.
It
is likely to be several years before tissues derived this way could
even be tested in patients, he and other experts said...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...